SLC18A2: A Potential Drug Target and Biomarker for Synaptic Transmission

Target Name: SLC18A2

NCBI ID: G6571

SLC18A2

SLC18A2: A Potential Drug Target and Biomarker for Synaptic Transmission

SLC18A2, a member of the SLC (sodium-dependent) chloride transport family, is a protein that plays a critical role in synaptic transmission, which is the process by which nerve signals are transmitted from the brain to the rest of the body. The SLC18A2 protein is expressed in high levels in the rat cerebral cortical spine, and its function is essential for the proper functioning of synaptic communication.

Recent studies have identified SLC18A2 as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. This is attributed to the fact that SLC18A2 is involved in the release of neurotransmitters, such as dopamine and serotonin, which are crucial for the transmission of signals in the brain.

Additionally, SLC18A2 has also been identified as a potential biomarker for various neurological disorders. The levels of SLC18A2 have been found to be decreased in individuals with Alzheimer's disease, which is a leading cause of dementia. This suggests that SLC18A2 may be a useful biomarker for the diagnosis and progression of Alzheimer's disease.

Another potential mechanism by which SLC18A2 may be involved in neurological disorders is its role in modulating the activity of other proteins. Studies have shown that SLC18A2 can interact with various neurotransmitter receptors, including dopamine, serotonin, and GABA. This interaction may play a role in modulating the activity of these neurotransmitters, which in turn can influence the behavior and cognition of the organism.

In addition to its potential role in drug targeting and biomarkering, SLC18A2 is also of interest as a potential therapeutic target for treating neurological disorders. The disruption of SLC18A2 has been shown to contribute to the development of various neurological disorders, including Alzheimer's disease and Parkinson's disease.

In conclusion, SLC18A2 is a protein that plays a critical role in synaptic transmission and has been identified as a potential drug target and biomarker for various neurological disorders. Further research is needed to fully understand the role of SLC18A2 in neurological function and to develop effective treatments for the disorders associated with its disruption.

Protein Name: Solute Carrier Family 18 Member A2

Functions: Electrogenic antiporter that exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis. Transports a variety of catecholamines such as dopamine, adrenaline and noradrenaline, histamine, and indolamines such as serotonin (PubMed:8643547, PubMed:23363473). Regulates the transvesicular monoaminergic gradient that determines the quantal size. Mediates somatodendritic dopamine release in hippocampal neurons, likely as part of a regulated secretory pathway that integrates retrograde synaptic signals (By similarity). Acts as a primary transporter for striatal dopamine loading ensuring impulse-dependent release of dopamine at the synaptic cleft (By similarity). Responsible for histamine and serotonin storage and subsequent corelease from mast cell granules (PubMed:8860238) (By similarity)

The "SLC18A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC18A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets